drugset / Trial / NCT00701805

Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)

NCT00701805

Phase 2 Completed 107 enrolled Abbott Abbott Japan Co.,Ltd · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety of paricalcitol injection. Subjects will administer clinical supplies 3 times a week, 40 weeks at dialysis session in dose-titration manner, following 12 weeks of treatment in the dose-response study, M10-309 (NCT00667576).

Timeline

Start
2008-07
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Paricalcitol Other / unclassified 2 ug Intravenous
Subject Paricalcitol Other / unclassified 4 ug Intravenous